Tango Therapeutics (TNGX) is having a Monday morning to remember. The biotech company's stock shot up more than 48% in premarket trading after it unveiled some eye-catching early data from a Phase 1/2 trial combining two experimental drugs, vopimetostat and daraxonrasib, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Pancreatic cancer is notoriously tough to treat, so any glimmer of hope tends to get investors' attention. Here, the numbers are hard to ignore: a 92% objective response rate, 90% progression-free survival at six months, and a 100% disease control rate. That's the kind of data that makes oncologists sit up and take notice. The company is already planning to push this combination into Phase 3 development as a first-line treatment for MTAP-deleted pancreatic cancer, with the goal of offering a chemotherapy-free option for patients.

But that's not all Tango had up its sleeve. The company also reported results from another arm of the trial testing opimetostat plus zoldonrasib. That combo delivered a 52% objective response rate, 74% six-month progression-free survival, and a 96% disease control rate. Solid numbers, though not quite as dazzling as the first pairing.

For context, pancreatic cancer has a five-year survival rate of just around 12%, and standard chemotherapy often comes with brutal side effects. A targeted, chemotherapy-free approach could be a game-changer if these results hold up in larger studies. Tango is essentially trying to rewrite the playbook for one of the deadliest cancers.

Now, let's talk about the stock itself. Tango Therapeutics has been on an absolute tear over the past year, up 386%. That's the kind of return that makes growth investors drool. But momentum can be fickle. The stock is currently trading 60.9% above its 20-day simple moving average of $21.75, which signals a strong bullish trend. However, the MACD indicator is sitting below its signal line, suggesting that the upside momentum might be losing steam unless it can reclaim that baseline. In plain English: the stock has run hard, and it might need to catch its breath.

Wall Street analysts are still largely on board. The consensus rating is a Buy, with an average price target of $31.78. Recent moves from the analyst community paint a mixed but still optimistic picture. Piper Sandler downgraded the stock to Neutral on May 15 but raised its price target to $24. Mizuho kept an Outperform rating and bumped its target to $30 the same day. Jefferies also downgraded to Hold on May 14 but lifted its forecast to $27. So while some analysts are tapping the brakes on the rating, they're still raising their price targets—a sign that they see value but want to manage expectations after such a massive run.

On the momentum front, Tango scores a 98.41 out of 100 on MarketDash's momentum metric, which compares its performance to the broader market. That's about as bullish as it gets. But as any seasoned investor knows, high momentum can cut both ways—when sentiment shifts, the fall can be just as dramatic.

As of premarket trading Monday, TNGX shares were changing hands at around $30, up 48.37% from Friday's close. Whether the stock can hold those gains through the regular session remains to be seen, but for now, Tango Therapeutics is the center of attention in the biotech world.